Institutional Investors Are Crazy For Merck Sharp & Dohme Corp (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) Logo

Sentiment for Merck Sharp & Dohme Corp (NYSE:MRK)

Merck Sharp & Dohme Corp (NYSE:MRK) institutional sentiment increased to 1.09 in 2019 Q2. Its up 0.28, from 0.81 in 2019Q1. The ratio has increased, as 708 funds opened new and increased holdings, while 649 reduced and sold stock positions in Merck Sharp & Dohme Corp. The funds in our partner’s database now have: 1.83 billion shares, down from 1.86 billion shares in 2019Q1. Also, the number of funds holding Merck Sharp & Dohme Corp in their top 10 holdings decreased from 144 to 122 for a decrease of 22. Sold All: 53 Reduced: 596 Increased: 565 New Position: 143.

Merck & Co., Inc. provides healthcare solutions worldwide. The company has market cap of $211.33 billion. It operates in four divisions: Pharmaceutical, Animal Health, Healthcare Services, and Alliances divisions. It has a 23.15 P/E ratio. The firm offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

The stock decreased 0.27% or $0.22 during the last trading session, reaching $82.54. About 4.71M shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 28.05% since September 13, 2018 and is uptrending. It has outperformed by 28.05% the S&P500.

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on October, 24. They expect $1.25 earnings per share, up 5.04 % or $0.06 from last year’s $1.19 per share. MRK’s profit will be $3.20B for 16.51 P/E if the $1.25 EPS becomes a reality. After $1.30 actual earnings per share reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts -3.85 % negative EPS growth.

Srb Corp holds 14.42% of its portfolio in Merck & Co., Inc. for 1.84 million shares. Terril Brothers Inc. owns 224,533 shares or 6% of their US portfolio. Moreover, Foundation Resource Management Inc has 5.67% invested in the company for 330,729 shares. The United Kingdom-based Parus Finance (Uk) Ltd has invested 5.45% in the stock. Wilkins Investment Counsel Inc, a Massachusetts-based fund reported 207,693 shares.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Ratings analysis reveals 100% of Merck & Company’s analysts are positive. Out of 4 Wall Street analysts rating Merck & Company, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $8400 while the high is $10300. The stock’s average target of $93.60 is 13.40% above today’s ($82.54) share price. MRK was included in 13 notes of analysts from March 22, 2019. The firm has “Buy” rating given on Friday, June 21 by Bank of America. Morgan Stanley maintained Merck & Co., Inc. (NYSE:MRK) on Friday, June 21 with “Buy” rating. The rating was maintained by Cantor Fitzgerald on Friday, March 22 with “Buy”.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: which released: “Merck (MRK) Pooled Analysis Continues to Show its KEYTRUDA in Combination with Chemotherapy Improved OS for Patients with Advanced NSCLC –” on September 10, 2019, also with their article: “Merck & Co., Inc.’s (MRK) Management Presents at Morgan Stanley 17th Annual Global Healthcare Conference 2019 – Transcript – Seeking Alpha” published on September 09, 2019, published: “Can Merck & Co., Inc.’s (NYSE:MRK) ROE Continue To Surpass The Industry Average? – Yahoo Finance” on September 02, 2019. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: and their article: “How Important Is Keytruda For Merck? – Forbes” published on August 29, 2019 as well as‘s news article titled: “Merck (MRK) Announces Pivotal New Data from its Broad Oncology Portfolio at ESMO –” with publication date: September 09, 2019.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.